The prevalence and antibiotics resistance profile of Burkholderia cepacia in neonatal sepsis: a pioneer study in Kurdistan Region-Iraq
Letters in Applied Microbiology · 2026
DOI: 10.1093/lambio/ovag012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Applied Microbiology, 2026. Verfasst von Marwa S Ibrahim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Technology, College of Health and Medical Technology - Shekhan, Duhok Polytechnic University, Duhok, 42001, Kurdista…. Hauptthemen laut MEDLINE: Burkholderia cepacia, Neonatal Sepsis, Burkholderia Infections, Anti-Bacterial Agents. Die Arbeit nennt 34 Literaturangaben.
Themen: Sepsis
Abstract (Originalsprache)
Burkholderia cepacia (B. cepacia) is Gram-negative, multidrug-resistant bacteria that can infect neonates and hospitalized patients, often spreading through contaminated medical devices. It causes various infections including sepsis, and it is difficult to treat due its antibiotic resistance. Over a three-year period (2021–2023), data from the ICU at Hevi Pediatric Teaching Hospital were reviewed and analyzed. Sepsis cases were identified based on clinical signs and confirmed through blood culture. B. cepacia identification and sensitivity test were confirmed using the VITEK system. Out of a total 1046 blood samples, 524 (50.1%) demonstrated positive bacterial growth, among which 142 (27.1%) identified as B. cepacia sepsis. The total neonatal cases counted for 123, 112 (91.1%) occurred in males and 11(8.9%) in females. Early-onset sepsis (EOS, ≤72 h) accounted for 49 cases (39.8%) and late-onset sepsis (LOS, > 72 h) for 74 (60.2%). The overall in-hospital mortality rate was 10.6% (13/123). Notably, B. cepacia isolates exhibited extensive multidrug resistance. Only a limited number of antimicrobials, including meropenem (3% resistance), ceftazidime (5%) and trimethoprim/sulfamethoxazole (9%) demonstrated promising results. These findings underscore an urgent need for coordinated interventions, emphasizing prudent antibiotic use and the strengthening of antimicrobial stewardship program to mitigate further resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Laboratory Technology, College of Health and Medical Technology - Shekhan, Duhok Polytechnic University, Duhok, 42001, Kurdistan Region, Iraq.
- Department of Biology, Collage of Science, University of Duhok, Duhok, 42001, Kurdistan Region, Iraq.
- Hevi Pediatrics Teaching Hospital, Duhok Health Directorate, Duhok, 42001, Kurdistan Region, Iraq.
- Pediatrics Department, College of Medicine, University of Duhok, Duhok, 42001, Kurdistan Region, Iraq.
- Medical Laboratory Sciences, College of Science, University of Nawroz, Duhok, 42001, Kurdistan Region, Iraq.
- Department of Biology, College of Sciences, University of Zakho, Zakho, 42001, Kurdistan Region, Iraq.
ORCID-Profile: Marwa S Ibrahim, Delveen R Ibrahim, Azad A Haleem, Abdulrahman T Saadi, Khalid S Ibrahim
Zitieren
APA
Ibrahim, M. S., Ibrahim, D. R., Haleem, A. A., Yahya, N. B., Saadi, A. T., Abdulaziz, S. S., Hasqyal, R. Y., & Ibrahim, K. S. (2026). The prevalence and antibiotics resistance profile of Burkholderia cepacia in neonatal sepsis: a pioneer study in Kurdistan Region-Iraq. Letters in Applied Microbiology. https://doi.org/10.1093/lambio/ovag012
Vancouver
Ibrahim MS, Ibrahim DR, Haleem AA, Yahya NB, Saadi AT, Abdulaziz SS, et al. The prevalence and antibiotics resistance profile of Burkholderia cepacia in neonatal sepsis: a pioneer study in Kurdistan Region-Iraq. Letters in Applied Microbiology. 2026. doi:10.1093/lambio/ovag012
BibTeX
@article{Ibrahim2026,
author = {Ibrahim, Marwa S and Ibrahim, Delveen R and Haleem, Azad A and Yahya, Nizar B and Saadi, Abdulrahman T and Abdulaziz, Sawsan S and Hasqyal, Revan Y and Ibrahim, Khalid S},
title = {The prevalence and antibiotics resistance profile of Burkholderia cepacia in neonatal sepsis: a pioneer study in Kurdistan Region-Iraq},
journal = {Letters in Applied Microbiology},
year = {2026},
doi = {10.1093/lambio/ovag012}
}
EUVIMED